Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies

  • Thomas Prebet, Jacques Delaunay, Eric Wattel, Thorsten Braun, Pascale Cony-Makhoul, Sophie Dimicoli, Stephan Wickenhauser, Julie Lejeune, Sylvie Chevret, Fatiha Chermat, Pierre Fenaux, Norbert Vey
  • British Journal of Haematology, December 2016, Wiley
  • DOI: 10.1111/bjh.14427

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1111/bjh.14427

In partnership with: